Back to top

Analyst Blog

Jazz Pharmaceuticals plc (JAZZ - Analyst Report) recently discussed its product portfolio and pipeline. Key products in the company’s portfolio include Xyrem, Erwinaze and Prialt.

Xyrem (sodium oxybate) is available in the US market since 2002 for cataplexy and excessive daytime sleepiness in narcolepsy. The specialty biopharmaceutical company stated that it expects to meet the guidance of Xyrem 2012 sales ranging $375-$380 million, announced in Nov 2012. The company is currently facing patent challenges for Xyrem. Two abbreviated new drug applications (ANDA) have been filed out of which litigation going on with one.

Jazz Pharma added Erwinaze (asparaginase Erwinia chrysanthemi) to its product portfolio following its EUSA Pharma acquisition in Jun 2012. Erwinaze is used for the treatment of patients suffering from acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy. The company expects to exceed the guidance of $125-$129 million in 2012. The product enjoys orphan drug exclusivity in the US till Nov 2018.

The company has initiated a study evaluating intravenous formulation Erwinaze. Jazz Pharma expects preliminary pharmacokinetic data from the study in the second half of 2013.

Jazz Pharma added chronic pain treatment Prialt to its product portfolio through its acquisition of Azur Pharma in Jan 2012. In the first half of 2013, the company intends to initiate a registry trial for the drug to provide additional data on the drug.

Moveover, a phase III trial evaluating Leukotac for the treatment of steroid-refractory acute graft versus host disease is ongoing in the EU. Data from the trial is expected to be released in the end of 2014 or early 2015.

Currently, we have a Neutral recommendation on Jazz Pharma. The stock carries a Zacks Rank #3 (Hold rating) in the short run.

Pharma stocks, which currently look more attractive, are Targacept Inc. (TRGT - Snapshot Report) and Valeant Pharmaceuticals (VRX - Analyst Report). Both these companies carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%